United Therapeutics Corp. SEC Filings

United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO (also a Director). On 10/13/2025 and 10/14/2025, the executive exercised 4,000 stock options each day at an exercise price of $120.26 per share (total 8,000 shares), and sold a total of 8,000 shares in multiple trades. Reported sale prices included $437.53, $441.26, $432.74, and weighted averages of $441.4 (range $441.085–$442.07) and $434.0077 (range $434.00–$434.145).

Following these transactions, direct holdings were 130 shares. Indirect holdings were reported as 166 shares by spouse and trusts holding 324,518, 258,117, 45,596, and 15,962 shares. Derivative securities beneficially owned following the reported transactions totaled 186,000 stock options.

The activity was conducted under a pre-arranged Rule 10b5-1 trading plan entered on May 2, 2025, which continues until the earlier of exhausting a 294,000-option tranche expiring March 15, 2026, or December 31, 2025.

United Therapeutics (UTHR) executive action: The company’s President and COO reported option exercises and same‑day share sales on 10/13/2025 under a Rule 10b5‑1 plan entered into on June 3, 2025.

Two option tranches were exercised: 14,625 options at an exercise price of $135.42 and 7,875 options at $146.03. The resulting shares were sold at $440.3539 per share through trusts referenced in the filing. Following these transactions, direct ownership stood at 2,648 shares, while derivative holdings remained, including options indirectly held through the noted trusts.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and open-market sales under a 10b5-1 plan. On 10/09/2025 and 10/10/2025 she exercised 8,000 stock options with an exercise price of $120.26 each, converting them into 8,000 shares. Concurrently, she sold a total of 8,000 shares in multiple trades at weighted-average prices ranging from $442.96 to $451.24.

After these transactions, Ms. Rothblatt directly owned 130 shares; additional indirect holdings include 324,518, 258,117, 45,596, and 15,962 shares held in various trusts, and 166 shares held indirectly by spouse, reflecting continued substantial family trust ownership and ongoing option tranches expiring 03/15/2026.

UNITED THERAPEUTICS (UTHR) filed a Form 144 disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,778,788.40, slated for 10/10/2025 on NASDAQ. The filing shows the shares were originally acquired on 03/15/2016 as executive deferred compensation from Martine Rothblatt, with 294,000 shares acquired in that transaction and payment made via vested options exercised with common shares. The notice also lists multiple recent sales by the same person totaling 88,000 shares sold across dates from 09/09/2025 to 10/09/2025, with individual daily proceeds ranging roughly from $1.59M to $1.81M. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 language where applicable.

United Therapeutics (UTHR) insider sale notice: An officer/director-level holder filed a Form 144 to sell 4,000 common shares with an aggregate market value of $1,795,655.20 planned on 10/09/2025 through TD Securities (USA) LLC on the NASDAQ. The filing shows these shares were originally acquired on 03/15/2016 via executive deferred compensation from Martine Rothblatt and were exercised via vested options with payment made in common shares. The filing also lists multiple recent disposals of common shares by Martine Rothblatt on dates across 09/09/2025 to 10/08/2025, each transaction showing 4,000 shares on most dates and one 8,000-share sale on 09/09/2025, with individual gross proceeds reported per trade. The filer certifies no undisclosed material adverse information and includes routine signature/attestation language.

United Therapeutics (UTHR) Form 144 shows a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,803,449.20 and an approximate sale date of 10/08/2025. The filing reports the shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement and notes 294,000 shares were acquired at that time via exercised options paid with common shares.

The notice lists numerous sales by Martine Rothblatt during 09/09/2025–10/07/2025, typically in blocks of 4,000 shares per transaction, with gross proceeds shown for each date. The filing states the seller represents no undisclosed material adverse information about the issuer.

United Therapeutics director and CEO Martine A. Rothblatt executed and sold stock under a pre-arranged 10b5-1 trading plan entered 05/02/2025. On 10/07/2025 and 10/08/2025 she exercised a total of 8,000 stock options with an exercise price of $120.26 per share, converting those options into 8,000 common shares. Simultaneously, the reporting person sold a total of 8,000 common shares in multiple transactions at weighted-average prices in the mid-$440s to mid-$450s, with reported weighted averages and price ranges disclosed for the trades. Following these transactions, the reporting person reports 202,000 options remaining exercisable and various indirect holdings: 324,518, 258,117, 45,596, and 15,962 shares held in family trusts and 166 shares held indirectly by spouse. The Form 4 states the 10b5-1 plan will continue until the earlier of exhaustion of a tranche of 294,000 stock options expiring 03/15/2026 or 12/31/2025.

Insider exercise and sales under a 10b5-1 plan on 10/06/2025

The President and COO of United Therapeutics (UTHR) exercised a total of 22,500 stock options on 10/06/2025 (14,625 options at a $135.42 strike; 7,875 at $146.03) and immediately sold many of the resulting shares from trusts for which he has shared or sole trustee powers. Multiple sales were executed in tranches with weighted‑average prices reported in the range of approximately $449.45 to $454.81, with specific weighted averages shown (for example, $449.82, $450.97, $452.03, $453.16, $253.975). Transactions were made pursuant to a Rule 10b5‑1 trading plan established on 06/03/2025. Following the reported transactions, the reporting person beneficially owned optioned shares and remaining common stock indirectly through trusts, with listed post‑transaction holdings such as 14,325 and 7,875 underlying shares shown for the respective option series.

UNITED THERAPEUTICS (UTHR) reported a Rule 144 notice disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,807,320. The filing shows these shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, and payment was made by exercising vested options with shares used for payment. The issuer has 45,230,000 shares outstanding, so the single proposed block equals roughly 0.009% of outstanding stock. The filing also itemizes prior open-market sales by the same person totaling 80,000 shares over the past three months, generating multi‑million dollar proceeds on multiple dates.